EBIO Insider Trading Activity and SEC Form 4 Filings
EBIO insider trading summary
No open-market insider purchases or sales of Eleven Biotherapeutics, Inc. (EBIO) have been reported on SEC Form 4 in the past 12 months.
Latest EBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 14, 2017 | John J McCabe | Chief Financial Officer | Sell | $3K (1,399 @ $2.10) |
| Sep 28, 2016 | Abbie Celniker | Director | Sell | $30K (10,031 @ $3.00) |
| Sep 23, 2016 | Flagship Ventures 2007 General Partner LLC | 10% Owner | Sell | $128K (41,178 @ $3.10) |
| Sep 23, 2016 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Sell | $39K (12,482 @ $3.16) |
| Sep 23, 2016 | Flagship Ventures Fund 2007, L.P. | 10% Owner | Sell | $10K (3,118 @ $3.16) |
| Sep 23, 2016 | Flagship Ventures Fund IV-Rx, L.P. | 10% Owner | Sell | $10K (3,118 @ $3.16) |
| Sep 23, 2016 | Edwin M Kania Jr | 10% Owner | Sell | $10K (3,118 @ $3.16) |
| Sep 23, 2016 | Flagship Ventures Fund IV, L.P. | 10% Owner | Sell | $39K (12,482 @ $3.16) |
| Sep 23, 2016 | Flagship Ventures 2007 General Partner LLC | 10% Owner | Sell | $39K (12,482 @ $3.16) |
| Sep 23, 2016 | Flagship Ventures Fund IV, L.P. | 10% Owner | Sell | $10K (3,118 @ $3.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.